Delisting risk
Longeveron
Develops donor-derived cell therapy for pediatric cardiac and aging-related diseases.
$6.72
After-hours close0.00 (0.00%)
At close$6.72(−1.18%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.63 | — | — |
| Aug 2026 | −$0.18 | −$0.19 | −8.6% |
| May 2026 | −$0.19 | −$0.19 | 0.0% |
| Mar 2026 | −$0.42 | −$0.22 | +47.6% |
| Nov 2025 | −$0.26 | −$0.39 | −50.0% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | −$1.63 | — | — | $400.0K | — | — |
| Aug 12, 2026 | −$0.18 | −$0.19 | −8.6% | $326.0K | $287.0K | −12.0% |
| May 13, 2026 | −$0.19 | −$0.19 | 0.0% | $334.5K | $398.0K | +19.0% |
| Mar 17, 2026 | −$0.42 | −$0.22 | +47.6% | $110.3K | $365.0K | +230.8% |
| Nov 4, 2025 | −$0.26 | −$0.39 | −50.0% | $110.3K | $137.0K | +24.2% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Aug 13, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 28, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 14, 2024 | ||||||
| May 14, 2024 | ||||||
| Feb 27, 2024 | ||||||
| Nov 10, 2023 | ||||||
| Aug 11, 2023 | ||||||
| May 12, 2023 | ||||||
| Mar 10, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Aug 12, 2022 | ||||||
| May 13, 2022 | ||||||
| Mar 11, 2022 | ||||||
| Nov 12, 2021 | ||||||
| Aug 13, 2021 | ||||||
| May 14, 2021 | ||||||
| Mar 30, 2021 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||